PD-1 regulates latent effector differentiation of thymic cytotoxic CD8+ T cells
Durable T cell immunity against cancer depends on the continual replenishment of effector CD8⁺ T cells. Thymic output has been associated with favorable prognosis in cancer patients across a range of ages, suggesting that the thymus is an important source for replenishing T cells capable of controlling cancer progression. However, whether CD8⁺ T cells acquire effector potential within the thymus, and how thymic output of effector CD8⁺ T cells contribute to peripheral tumor immunity, remain unclear. In this study, we discover that thymic single-positive (SP) CD8⁺ T cells undergo latent effector differentiation following thymic selection, but this process is subject to PD-1 regulation. We further demonstrate that PD-1 limits the contribution of thymic output of CD8⁺ T cells in shaping the TCR repertoire within the tumor tissues for tumor immunosurveillance. Although PD-1 inhibition facilitates the expansion of effector CD8⁺ T cells in the periphery, these cells gradually lose antitumor activity within tumors due to accelerated exhaustion in the absence of PD-1. Thus, while latent effector differentiation of thymic CD8⁺ T cells enables a rapid response to malignant cells in the periphery, PD-1 restrains this process to prevent overt or terminal effector differentiation, which may compromise balanced and durable peripheral immunity.
Authors
- Henrique Borges da Silva (ORCID: https://orcid.org/0000-0001-9424-3326)
- Adrian T. Ting (ORCID: https://orcid.org/0000-0003-0653-9923)
- Joanina K. Gicobi (ORCID: https://orcid.org/0000-0002-2741-0363)
- Zhiming Mao (ORCID: https://orcid.org/0000-0002-7705-9575)
- Jacob J. Teske (ORCID: https://orcid.org/0000-0002-3361-5859)
- Fabrice Lucien (ORCID: https://orcid.org/0000-0001-6149-345X)
- Jacob B. Hirdler
- Aubrey Y. Liew
- Emilia R. Dellacecca
- Daniel D. Billadeau (ORCID: https://orcid.org/0000-0002-2296-9547)
- Virginia M. Shapiro (ORCID: https://orcid.org/0000-0001-9978-341X)
- Li Ding
- Ying Li
- Michelle A. Hsu (ORCID: https://orcid.org/0000-0002-3214-2607)
- Haidong Dong (ORCID: https://orcid.org/0000-0002-5782-2983)
- Geoffrey Zhao (ORCID: https://orcid.org/0009-0000-0610-2321)
- Wenjing Zhang
- Mark A. Maynes
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-05-23
- DOI
- https://doi.org/10.1038/s41467-026-73392-7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Office of Extramural Research, National Institutes of Health